NCT01977755View on ClinicalTrials.gov

Phase 2 Clinical Proof-of-Concept Study of the Cardioprotective Properties of Danegaptide in ST Segment Elevation Myocardial Infarction

PHASE2CompletedINTERVENTIONAL
Enrollment

591

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

December 20, 2015

Study Completion Date

June 8, 2016

Conditions
Focus of Study is STEMI
Interventions
DRUG

danegaptide

DRUG

Placebo

Trial Locations (1)

2100

The Heart Center, Rigshospitalet, University of Copenhagen, Copenhagen

Sponsors

Lead Sponsor

Zealand Pharma
All Listed Sponsors
lead

Zealand Pharma

INDUSTRY

NCT01977755 - Phase 2 Clinical Proof-of-Concept Study of the Cardioprotective Properties of Danegaptide in ST Segment Elevation Myocardial Infarction | Biotech Hunter | Biotech Hunter